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There has been a rapid accumulation of evidence
indicating that the metabolism of many amino acids
and proteins is altered in advanced renal failure.
These abnormalities can be classified according to
whether they are similar to those found in protein-
calorie malnutrition or are secondary to uremia.
Those alterations which are consistent with wast-
ing or malnutrition (Table I) include decreased
body weight, fat, fat-free solids, and intracellular
water [1—3]. Many serum proteins, e.g., albumin,
transferrin, cholinesterase, and several components
of the complement system, are reduced [2, 3, 5—7].
Plasma concentrations of valine, leucine, isoleu-
cine, lysine, tryptophan, and tyrosine are reduced:
glycine is often increased [8—10]. The ratios of
essential to nonessential amino acids, of Va-
line:glycine and tyrosine:phenylalanine in plasma
are low [2, 3, 5, 8]. Other alterations in plasma
amino acids do not appear to be caused by nutri-
tional disorders. These include increased plasma
concentrations of citrulline, cystine, hydroxy-
proline, and 1- and 3-methylhistidine [8, 9] (see also
Alvestrand et al; Holliday and Chantler, this issue).
Plasma protein metabolism
Patients with chronic renal failure have a normal
to increased intravascular volume and a normal in-
travascular pool of albumin. Extracellular and total
albumin pools are decreased [12, 13]. Absolute
rates of synthesis and catabolism of albumin are re-
duced [12, 13]. In clinically stable dialysis patients,
the intravascular pool and absolute catabolic rate of
intravascular albumin are somewhat increased, and
the fractional catabolic rate is normal [12, 14, 171.
Grossman, et al [18] studied rats with renal failure
and found serum albumin concentration was low,
but intracellular albumin concentration in liver was
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high—particularly in the free cytosol fraction. Syn-
thesis of albumin and total protein in membrane-
bound polysomes was decreased; synthesis of pro-
tein in free polysomes was normal. Since dietary
intakes of the control and uremic rats were similar,
the disturbances in albumin and protein metabolism
in the uremic rats may have been due to nonnutri-
tional factors. Nonetheless, in uremic patients,
serum albumin concentrations often fall during
periods of poor nutritional intake, and improved
nutrition is often associated with increased serum
concentrations of albumin and other proteins [5—7,
19, 20].
Alterations in other small proteins, e.g., in-
creased serum concentrations of a1-microglobulin
[21], $2-microglobulin [22, 23], lysozymes [23, 24],
retinol-binding protein [7, 23, 25], a1-acid glycopro-
tein [7], prealbumin [5, 7, 23], ribonuclease [24, 26],
fibrinogen degradation products [271, gamma globu-
lin light chains and Bence-Jones proteins [28] also
are seen in uremia and do not appear to be caused
by nutritional disorders. Peptides, middle mole-
cules [29], and a large number of metabolites of
amino acids and proteins are increased in body
fluids [8]. Many of these foregoing abnormalities
have not been observed in every study of uremia;
the evidence suggests, however, that they are not
common.
Most of these aberrations in amino acid and pro-
tein metabolism have been observed in serum or
plasma because of the ease of sampling and mea-
surement of blood. This approach has led to accu-
mulation of data that are descriptive, and to this ex-
tent the pathogenesis of these alterations is not un-
derstood. Certain factors, however, are recognized
as causal, and these will be discussed.
Dietary intake of protein and energy
Nutritional disorders are particularly important
as causes of altered protein metabolism in uremia.
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Table 1. Evidence for wasting or malnutrition in uremia
Decreased
Body weight [1—3]
Height (children) 141
Growth (children) [4]
Body fat [1, 3]
Anthropometric
Biochemical
Decreased
Fat free solids [1]
Intracellular water [1]
Muscle mass [3]
Skinfold thickness [3]
Decreased
Serum
Total protein [3, 6]
Albumin [3, 61
Transferrin [2, 3, 5—7]
Clq [6]
C3 [3, 5—7]
C3c [6]
CIs inactivator [6]
C3 activator [6, 7]
Cholinesterase [7]
Plasma
Leucine 18, 9]
Isoleucine [8,91
Total tryptophan [8]
Valine [8—10]
Tyrosine [8, 9]
Valine/glycine ratio [2, 3, 81
Essential/nonessential ratio [2,3,5,8]
Normal or increased
Plasma
Total nonessential amino acids [8]
Glycine [8, 9]
Decreased
Muscle alkali soluble protein [11]
Total albumin mass, synthiesis.
and catabolism 112—14]
Valine pools (nondialyzed patients) [10]
Potassium [15, 16]
Both nondialyzed chronically uremic patients and
those undergoing maintenance hemodialysis or
peritoneal dialysis frequently ingest inadequate
quantities of nutrients. This is especially common
among dialysis patients since their requirements for
protein, certain vitamins, and possibly other nutri-
ents may be higher than normal because of losses
during dialysis. They also may be deficient in calo-
ries and some vitamins and minerals because their
food intake is often depressed. Poor food intake or
anorexia may be caused by uremic toxicity, medici-
nal intake, emotional depression, or dietary con-
straints 1141. Patients may also become malnourished
because illnesses or medical procedures may pre-
vent intake of food or cause anorexia.
We evaluated protein and energy intake during a
12-month period in 35 men undergoing maintenance
hemodialysis. The average daily protein intake for
the 12-month period of study was similar to that
commonly prescribed for hemodialysis patients—
1.0 g!kg of body wt per day. Only 2 of 35 patients
had a mean protein intake less than 0.75 glkglday,
whereas 9 had an energy intake less than 75% of the
RDA [30] for normals. On the other hand, 3 of 35
patients ingested excess protein (greater than 1.25
g/kg!day), and no patients ingested excess energy
(1.25 x RDA). Although these definitions of defi-
ciency and excess are arbitrary, they indicate the
difference in intake patterns of protein and energy
in patients with uremia. Marked decreases in pro-
tein and energy intake were frequent in individual
patients during and immediately after dialysis and
during intercurrent illnesses. In patients undergoing
maintenance hemodialysis, evidence for malnutri-
tion is more common in those who have fluctuating
food intakes [31]. These findings are consistent with
the observation that food deprivation exceeding 14
hr in chronically uremic rats is associated with
greater protein breakdown than that which occurs
in control rats [32].
In summary, compared with recommended diet-
ary allowances for normal people, the protein in-
take of most patients on hemodialysis is normal to
high, whereas energy intake is apt to be low. Fre-
quent regular feedings may be beneficial.
The dialysis process
The dialysis process perturbs nutritional status
and affects amino acid and protein metabolism.
Many nutrients, amino acids, peptides, glucose,
a For many of the parameters listed in this table, normal values have sometimes been reported in patients with renal failure. Under
these circumstances, the abnormality has been listed only when the data suggest that the abnormality occurs not uncommonly in such
patients.b Brackets denote reference source of data.
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water-soluble vitamins, potassium, and phosphorus
are lost during dialysis. Plasma proteins are re-
moved during peritoneal dialysis [33]. Most trace
elements are protein bound, and little, if any, seem
to be lost during dialysis. Indeed, net transfer of
trace elements into patients frequently occurs dur-
ing dialysis, even when only small amounts are
present in the dialysate [34]. An exception may be
rubidium, which is often low in tissues of uremic
patients [35].
Approximately 5 to 8 g of free amino acids and 3
to 4 g of bound amino acids are removed during a 4-
hr hemodialysis in fasted patients. Ingestion of food
increases the losses slightly [36]. The quantity re-
moved may be greater with newer dialysis mem-
branes, which have larger surface areas or pore
sizes. Losses may differ with hemofiltration and
charcoal absorption. Adding glucose to dialysate
reduces amino acid losses [36] because glucose
lowers plasma concentrations of amino acids. Al-
though losses are derived directly from plasma,
their origin is largely from intracellular pools, and
these losses may affect protein synthesis or degra-
dation in cells.
Removal of glucose during hemodialysis is anoth-
er cause for amino acid and protein depletion. Dur-
ing hemodialysis with glucose-free dialysate, nor-
moglycemic patients lose approximately 20 to 50 g
of glucose into dialysate [33, 37]. Glucose losses in
patients who do not eat during dialysis may enhance
gluconeogenesis [37]. Glycogen stores of these pa-
tients often are limited, particularly in fasting or
poorly nourished patients, so that glucose gener-
ated to replace that lost during dialysis may be
largely derived from protein. Since poor food intake
is common during dialysis, the safest course is to
routinely administer glucose intravenously or in
dialysate if patients are not hyperglycemic.
Patients who eat a meal, i.e., protein and car-
bohydrate, during dialysis may minimize per-
turbations caused by losses of amino acids and glu-
cose. We have preliminary evidence, however, that
gastrointestinal movement of food may be impaired
in some patients during dialysis. Ingested food may
not be well absorbed until dialysis has ended—a
problem which would seem to merit further investi-
gation (see "Gastrointestinal tract in uremia," this
article).
Another source of protein depletion in patients on
hemodialysis is blood loss. This occurs from blood-
sampling, by sequestration of blood in the dialyzer
and blood lines, from blood leaks into the dialyzer,
and from bleeding at the dialysis access site. The
volume of blood retained in the dialyzer and blood
lines depends on the type of dialyzer and the tech-
niques of rinsing [38, 39]. With careful flushing of
dialyzers, blood loss can be reduced [38]. Occult
fecal blood loss occurs in dialysis patients [39, 40].
Proteinuria rarely is sufficient in magnitude to con-
tribute to protein depletion.
fffects of other nutrients
The dietary intake and metabolism of other nutri-
ents are altered in renal failure, and these altera-
tions may affect amino acid and protein metabo-
lism. Alterations in lipids, carbohydrates, calcium,
phosphorus, magnesium, sodium, potassium, trace
elements (such as iron, zinc, copper, and aluminum),
water-soluble vitamins, especially B6 (pyridoxine),
folic acid, and C, and fat-soluble vitamins A and D
may affect protein metabolism [33, 411.
Vitamin B (pyridoxine) deficiency occurs in pa-
tients with uremia, particularly those on dialysis;
drugs which interfere with pyridoxine metabolism,
removal of B6 by dialysis, and possibly accelerated
turnover of pyridoxine contribute to the potential
for B6 deficiency in renal failure [41, 42]. Vitamin B6
is a cofactor for a large number of enzymatic reac-
tions involving amino acid metabolism, including
transamination, decarboxylation, and deamination.
B6 is also involved in fatty acid metabolism and is
necessary for normal immunological activity, host
resistance, and neurological function. Patients un-
dergoing dialysis who do not receive supplementa-
tion with B6 show a defect in 3H-thymidine uptake
in mixed lymphocyte culture. Giving the patients
pyridoxine hydrochloride corrects this abnormality
[43]. In our experience, the minimum dietary sup-
plement of pyridoxine hydrochloride necessary to
correct or prevent B6 deficiency in all patients un-
dergoing maintenance hemodialysis is about 10 mgI
day. This dose is above the RDA of pyridoxine and
exceeds the usual dietary intake of this vitamin and
the pyridoxine content of most vitamin supple-
ments.
Patients with uremia who are not receiving folic
acid supplements [41] may show signs of folic acid
deficiency. Folate metabolism may be impaired,
e.g., transport into cells of the folate analog, metho-
trexate, is inhibited by uremic serum [44]. These in-
hibitors in uremic serum are dialyzable and possibly
are retained anions. Binding of folate to serum pro-
teins also is increased in azotemic patients [45].
These findings suggest that even in the presence of
normal serum folic acid concentrations in uremia,
there may be reduced transport into cells or abnor-
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mal binding to serum protein which might lead to a
state of folic acid deficiency.
Vitamin D affects muscle metabolism and func-
tion [46—481, and its deficiency has been implicated
in disordered muscle metabolism and myopathy.
Vitamin D deficiency may contribute to impaired
growth in renal failure [46, 48—51] (see also Avioli,
this issue). Mehis et at have reported increased food
intake and growth in uremic rats fed vitamin D sup-
plements compared with uremic rats not fed the
supplement [51]. They suggest that increased appe-
tite and food intake may contribute to the increased
growth observed with vitamin D supplements in
renal failure.
The relation between zinc metabolism and uremia
is puzzling. Zinc is a cofactor for a large number of
enzymes, some of which are involved with amino
acid metabolism [52]. Serum and hair zinc are either
low or normal [53—57], while red cell zinc concen-
trations are usually normal [53—55], and zinc con-
tent in many other tissues is either normal or in-
creased [35, 54, 58]. Interpretation of serum zinc
concentrations in uremia is difficult because most
serum zinc is bound to protein [591, and uremia may
affect protein binding independently of zinc stores.
This occurs in the case of tryptophan [60] and folate
(see above). Rats made acutely uremic by ureteral
ligation exhibit an abrupt fall in plasma zinc, a rise
in kidney zinc, and no change in zinc content of oth-
er tissues, suggesting that low serum zinc concen-
trations in uremia may be due to redistribution of
zinc pools [54]. Nonetheless, two reports suggest
that hemodialysis patients who are given zinc sup-
plements improve taste perception [56] and sexual
potency [57]. Simple zinc deficiency in children is
associated with poor appetite, retarded growth, and
delayed sexual maturation [61, 62]. The effects of
zinc supplementation have not been reported in ure-
mic children and further studies are needed to eva!-
uate the efficacy of zinc in uremic adults.
Potassium deficiency can alter protein and amino
acid metabolism. Total body potassium can be both
normal and decreased in renal failure [15, 16] (see
also Holliday and Chantler, this issue). When it is
decreased, it is difficult to determine whether this
indicates a selective deficiency in potassium or a de-
crease in cell mass. In chronically uremic patients
who are potassium deficient, the total body pool
may increase after commencement of repetitive
dialysis therapy 1161. In a small proportion of ure-
mic patients with normal potassium stores prior to
hemodialysis, however, chronic hemodialysis has
been associated with a fall in the total body pool.
Effects of urenic toxins
Uremic toxins may affect amino acid and protein
metabolism by altering enzyme activities [8], im-
pairing membrane transport [44], inhibiting protein-
binding [60], and predisposing to such untoward
clinical effects as anorexia, infection, and cardio-
vascular disease. The distinction between uremic
toxins and other metabolic abnormalities associated
with uremia is made mainly from the effects of pro-
tein restriction and dialysis therapy which lead to
marked improvement in some clinical and metabol-
ic abnormalities characteristic of uremia. Over 70
products of nitrogen metabolism have been shown
to be elevated in body fluids of uremic patients.
There is evidence for toxicity of urea, guanidines,
phenolic acids, and middle molecules [8].
Other products implicated in the pathogenesis of
the uremic syndrome which are not related to pro-
tein metabolism include myolnositol [63] and poly-
ols [64, 65]. The increased circulating concentra-
tions of these compounds may arise from decreased
urinary excretion, increased production, and/or re-
duced degradation.
Endocrine disorders that are characteristic of
uremia may also affect amino acid and protein me-
tabolism and promote wasting. Parathormone,
glucagon, insulin, growth hormone, prolactin, lute-
inizing hormone [661, and gastrin [67] often are in-
creased in serum. The concentrations of hormones
elaborated by the kidney, erythropoietin and 1,25-
dihydroxycholecalciferol (see also Avioli, this is-
sue) are reduced, and the activity of renin (more
correctly considered as an enzyme) may be in-
creased, normal, or decreased. Serum somatome-
din concentrations are reported to be reduced [68],
but this may be artifactual (see Potter and Greifer;
Levy and VanWyk, this issue).
Glucagon has catabolic effects on proteins and
amino acids. Severely uremic patients are more
sensitive to the action of glucagon, and this sensitiv-
ity is reversed by hemodialysis [69]. Hyper-
glucagonemia, however, is not reversed by dialysis
[691. During infusion of glucagon into uremic pa-
tients, plasma concentrations of certain amino acids
fall, whereas infusion in normal patients does not
have as marked an effect [69]. The liver from chron-
ically uremic rats shows increased binding sites for
glucagon and enhanced glucagon-stimulated adenyl
cyclase activity [70]. Insulin resistance is manifest-
ed by impaired peripheral action of insulin and glu-
cose intolerance [66]. Stimulation of glucose and
phosphorus uptake in the forearm by insulin is re-
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duced in uremic patients 1711. It is probable that the
effects of insulin on amino acid and protein metabo-
lism are impaired in uremia (see also Cheek; Hol-
liday and Chantler, this issue).
impaired rena/function
The diseased kidney directly affects amino acid
and protein metabolism because of its decreased ca-
pability to synthesize or catabolize certain hor-
mones and amino acids, to degrade peptides and
small proteins, and to produce or use certain amino
acids. The kidney has a major role in the degrada-
tion of many peptide hormones, e.g., insulin 1721,
glucagon [691, parathormone [73], thyrotropin [74],
and probably gastrin [67]. Peptides and low molecu-
lar weight proteins (< 50,000 daltons) readily tra-
verse the glomerulus and are reabsorbed and de-
graded by tubular cells. In uremia, the lower clear-
ance and decreased degradation of such compounds
by the diseased kidney are causes of their elevated
levels in the serum [21—23, 27, 28, 67, 69, 72—75].
Urinary excretion of some proteins is increased in
uremia [24, 76], possibly because of diminished
ability of renal tubular cells to catabolize the filtered
proteins.
The normal kidney has an important role in the
production and utilization of certain amino acids. It
is a major source for serine in humans and some
animals. The abnormally low ratio of plasma Se-
rine:glycine in renal failure may reflect impaired
synthesis of serine from glycine in the kidney 1771.
It may also contribute to the body homeostasis of
histidine, alanine, glutamic acid, and probably other
amino acids [78, 791. Asparagine, glutamine, and
glycine are metabolized in the kidney. During in-
take of amino acids, the pattern of production and
utilization changes, and many more amino acids are
metabolized by the kidney.
The fractional excretion of amino acids is usually
increased in advanced renal failure, but the absolute
quantity of amino acids excreted may be normal,
decreased, or increased. It has been speculated as
to whether enhanced urinary losses of amino acids
in renal failure might affect the plasma concentra-
tions and metabolism of amino acids, but the uri-
nary excretion in renal failure is so low relative to
the dietary intake that this possibility seems unlike-
ly 180, 81].
Gastrointestinal tract in uremia
Altered function of the gastrointestinal tract may
affect nitrogen metabolism of patients with uremia
either because the biochemical changes of uremia
directly affect mucosal cell function or because bac-
terial flora are altered by uremia.
The greatest interest has centered on urea metab-
olism in the gastrointestinal tract. Urea in the gut is
converted to ammonia, and ammonia concentra-
tions in gastrointestinal fluids are increased in ure-
mia [82—841. Urea concentrations in intestinal fluids
are low. Intestinal urease activity is correlated with
serum urea concentrations [85]. The absolute rate
of urea degradation, however, is increased slightly
if at all in uremia, and the fractional rate is greatly
decreased [86, 871. Giving antibiotics to patients de-
creases concentrations of gastric and fecal ammonia
and increases concentrations of fecal urea [83, 841.
Urea degradation and synthesis as determined by
kinetic studies also fall [88]. These observations
provide evidence that most of the nitrogen released
by hydrolysis of urea is converted back to urea in
the liver rather than used for de novo synthesis of
amino acids and proteins [86—88]. When patients,
however, are fed amino acid diets low in nitrogen
content, and then given supplemental urea, nitrogen
balance improves [89]. These and other studies sug-
gest that nitrogen released by hydrolysis of urea in
the gut may be used for synthesis of amino acids
only in patients whose total nitrogen intake is low
[89, 90].
Ammonia is derived from urea and from other
nonurea, nonprotein nitrogenous products in gas-
trointestinal fluid [84, 911. Increased ammonia pro-
duction in uremia may contribute to gastric hy-
poacidity [83].
Normally about one third of the uric acid pro-
duced is hydrolyzed in the gut; in renal failure a
greater proportion of uric acid is removed by extra-
renal routes [92—94]. Uric acid is metabolized to al-
lantoin, allantoic acid, ammonia, and carbon diox-
ide [92, 93]. Some of the carbon in uric acid appears
in urea 1931.
Other compounds are synthesized or degraded in
the gastrointestinal tract, e.g., dimethyl and tn-
methylamines [95, 96], creatinine [97, 98], choline
[99], indoles [100], and possibly guanidinosuccinic
acid [101]. Creatinine appears to be catabolized by
gut bacteria to sarcosine, methylamine, and methyl-
guanidine—a potential uremic toxin. Of the creati-
nine synthesized each day 16 to 66% may be de-
graded in uremic patients; comparable data for nor-
mal subjects are not available [97, 98].
Williams and Dick found increased nonprotein ni-
trogen in the liquid portion of diarrheal stool of ure-
mic patients [1021. In uremic men without diarrhea,
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however, fecal nitrogen losses were similar to nor-
mal men fed the same 40-g protein diets (about 1.3
of nitrogen per day) [8].
Uremic patients have greater numbers of in-
testinal bacteria, and bacteria are found as high as
the duodenum [95, 96]. Many of the metabolic con-
versions cited, e.g., those affecting urea and creati-
nine (see above), are largely the result of bacterial
action. Amine metabolism is affected by the bacte-
rial flora of the gut [96].
The effect of bacterial flora upon nitrogen metab-
olism in uremia has been suggested from the longer
survival of germ-free rats following nephrectomy.
Rats with partial bacterial colonization have inter-
mediate survival times [103]. The presence of colo-
nization affects the biochemical and pathological
manifestations of uremic rats [104]. In two uremic
patients given antibiotics which reduced intestinal
flora, there was a reduction in dimethylamine and
trimethylamine concentrations and an improvement
in neurological status [96]. Nitrogen balance im-
proves in uremic patients on a low-protein diet
when the patients are given nonabsorbable antibi-
otics [105]. The change is due primarily to a fall in
fecal nitrogen.
Diet management
The propensity for chronically uremic patients to
be malnourished or wasted has implications for
dietary management. Diets very low in nitrogen
may reduce uremic toxicity, but they also may pro-
mote wasting [33, 106]. Currently, in the treatment
of adults with far advanced renal failure, several
low-nitrogen diets have been used, including low
protein, low protein supplemented with essential
amino acids (EAA) or EAA and ketoacids, and
EAA as virtually the only source of nitrogen [89,
106—111]. Present evidence suggests that when the
GFR is 5 to 10 mI/mm, diets that provide 40 g of
protein (0.55 to 0.60 g/kg/day), primarily of high bio-
logical value, generally maintain neutral or positive
nitrogen balance and control uremic toxicity [33,
106, 111]. With GFRs <4 to 5 ml/min, the amino, or
ketoacid diets seem preferable because they can
usually maintain patients in nitrogen balance, and
engender lower rates of net urea production and
less uremic toxicity than the 40-g protein diets [107—
ill].
In some centers, oral or intravenous supplements
with EAA or ketoacids have been used for treat-
ment of dialysis patients [6, 112]. Experience varies
as to whether these supplements improve nutri-
tional status; it is likely that such supplements are
of value only when the protein intake is very low
(see also Holliday and Chantler, this issue).
The potential benefits of low-nitrogen diets pro-
viding protein, amino acids, or ketoacids must be
compared with treatment by maintenance dialysis
and more liberal intakes. These different therapies
should be evaluated in a multifactorial fashion in
which their effects on uremic toxicity, nitrogen bal-
ance, plasma and intracellular proteins and amino
acids, and cellular metabolism are assessed. A theo-
retical advantage to amino and ketoacid prepara-
tions is that they could be designed to correct al-
tered extracellular and intracellular amino acid con-
centrations [5, 108, 113] (see also Alvestrand et al,
this issue).
Summary
The many alterations in amino acid and protein
metabolism in renal failure are often poorly defined,
and the available data concerning them are usually
descriptive. Nonetheless, certain factors play an
important role in the altered amino acid and protein
metabolism of uremia. These include malnutrition
caused by poor nutrient intake, loss of nutrients
during dialysis, and abnormal metabolism of nutri-
ents. Other factors include uremic toxins, superim-
posed catabolic illnesses, endocrine disorders, and
the reduced capacity of the failing kidney to synthe-
size or degrade certain hormones, amino acids, pep-
tides, and small proteins. These aberrations have
complex interrelationships which sometimes poten-
tiate each other. It is possible that the administra-
tion of sufficient quantities of energy, vitamins, and
minerals, as well as the dietary manipulation of pro-
tein, amino acid and ketoacid intake may improve
the metabolism of amino acids and proteins. Vita-
min B6 and zinc have special requirements that may
affect protein or amino acid metabolism.
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